Azithromycin for Child Survival in Niger: Mortality and Resistance Trial

In the Mortality/Resistance trial, 3,000 communities in the Dosso and Tahoua regions of Niger will be randomized to one of three arms: 1) azithro 1-11: biannual oral azithromycin to children 1-11 months old with biannual oral placebo to children 12-59 months old, 2) azithro 1-59: biannual oral azithromycin to children 1-59 months old, or 3) placebo: biannual oral placebo to children 1-59 months old. Interventions will be delivered biannually through a door-to-door census. Mortality will also be monitored through biannual census data collection, which will be used to adaptively allocate treatment assignments after the first year. Communities will retain an allocation for 4 distributions before being re-randomized.

Antimicrobial resistance will be monitored using cluster sampling of treated and untreated children and adults in the Dosso region.

To compare costs, coverage, and acceptability of treating 1-11-month-old children only vs children 1-59 months old, an additional 80 communities in the Dosso region will be selected. These communities will be randomized in a 1:1 fashion to either receive 1) distribution of open-label azithromycin to children 1-11 months old with no intervention to children 12-59 months old or 2) distribution of open-label azithromycin to children 1-59 months old. The primary outcome for this substudy will be community-level costs per dose delivered. Secondary outcomes include program costs, treatment coverage, and acceptability of the intervention according to community leaders, community health workers, and caregivers of eligible children.

• Intervention

At the community-level, eligibility includes:

Inclusion criteria

• Location in Dosso, Tahoua, Maradi, Zinder, or Tillabéri regions
• Population 250 to 2,499*
• Distance > 5 km from district headquarters town
• Distinguishable from neighboring communities
• Verbal consent of community leader(s)

Exclusion criteria

• Inaccessible or unsafe for study team
• "Quartier" designation on national census *Population size as estimated from the most recent national census or projections

At the individual-level, eligibility includes:

Inclusion criteria

• Age 1-59 months
• Primary residence in a study community
• Verbal consent of caregiver/guardian for study participation
• Weight ≥ 3.0 kg (*no weight limits in communities using age-based dosing)

Exclusion criteria

• Known allergy to macrolides
• Population-based sample collections

At the community-level, eligibility includes:

Inclusion criteria

• Location in Dosso
• Distinguishable from neighboring communities
• Verbal consent of community leader(s)

Exclusion criteria

• Inaccessible or unsafe for the study team
• Included in MORDOR trials
• Not randomly selected
• Received treatment prior to sample collection

At the individual-level, eligibility includes:

Inclusion criteria

• Age 1-59 months or 7-12 years or caregiver/guardian of a child eligible for treatment
• Primary residence in a study community selected for sample collections
• Verbal consent of caregiver/guardian for study participation

Exclusion criteria

• An individual is not on the list of randomly selected participants from the census